Downloads

1. Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics 4/30/2026

   Designing repeat-dose RNA means engineering around immune recognition — optimizing payloads, purity, and delivery early to sustain efficacy, tolerability, and durability across multiple administrations.

2. A Novel Co-Tethered Transcription Platform For High-Yield, High-Purity mRNA Synthesis 4/15/2026

   Co-tethered transcription boosts mRNA yield and purity by organizing transcription machinery, reducing dsRNA impurities, and streamlining production for scalable RNA therapeutics.

3. Navigating GMP Biosafety Challenges In ATMP Manufacturing 3/26/2026

   BioPhorum's survey findings reveal a wide variation in how biosafety is managed within GMP environments for viral-based ATMPs, underscoring the need for harmonized guidance.

4. Proteomics Tools: A Resurrection 3/4/2026

   For decades, the evolution of proteomics has lagged. Now, a resurrection is underway. New tools are dismantling limitations, signifying a maturation of systems biology.

5. Beyond KRAS G12C: New Approaches For Drugging The Undruggable 2/20/2026

   RAS was considered among the holy grail of oncology targets, but over the past decade, this has started to change. A second wave is making its way through R&D to address current shortcomings.

6. Rethinking Disease Modification Through Targeted Immunotherapy 2/11/2026

   As understanding of immune-driven disease deepens, therapies that selectively correct dysregulated inflammation have the potential to reshape treatment paradigms.

7. Why Use Total Organic Carbon Analysis For Cleaning Validation? 1/21/2026

   Total organic carbon analysis is probably the most “fit for use” analytical method to validate cleaning processes, particularly within a science- and risk-based approach.

8. Rats Behind The Wheel: The Right Preclinical Way To Investigate Drug Effects On Driving? 12/8/2025

   What can we do preclinically for drug-induced impairment of driving ability? This article reviews the causes, regulatory environment, and limitations.

9. To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem 12/4/2025

   The choice of delivery dictates the complexity of manufacturing, which in turn determines the eventual cost and accessibility of the therapy.

10. Why Do So Few Cell Therapies Make The Leap From Lab To GMP? 11/5/2025

    Among other reasons, academic centers have access to sophisticated technology. In contrast, manufacturing suites must use established, validated methods.